Responses
Poster Presentations
Friday, 14 June 2019
SLE, Sjögren’s and APS – treatment
FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
Compose a Response to This Article
Other responses
No responses have been published for this article.